Pioneering approach to halting the chronic neuroinflammation responsible for neurodegeneration- Trial to assess safety, PK and detect early signs of efficacy- Initial data expected in mid-2026 ...

The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries NEW YORK, July 29, 2025 ...

A first-of-its-kind solution for women’s arousal in a proprietary topical formulation demonstrated to work where women need ...

On track to complete enrollment of first two cohorts of RAD204 following positive recommendation from DSMC to escalate dose ...

A NEW “game-changing” drug could stop the progression of Alzheimer’s disease, early trials suggest. Scientists say the treatment – called trontinemab – could be the ...

Nations that lead in clinical trials get earlier access to breakthrough therapies, shape global regulatory norms, and ...

Trontinemab is one of a class of new medicines aimed at clearing amyloid plaques. The new findings from phase two trials ...

The Phase III VIKTORIA-1 trial (NCT05501886) is evaluating a triple combination of gedatolisib, Ibrance (palbociclib) and Faslodex (fulvestrant), a double combination of gedatolisib and Faslodex ...

A research project led by the Ineos Oxford Institute for antimicrobial research (IOI) to study the cause and impact of ...

Decentralized Clinical Trials (DCTs) are transforming how we collect clinical data, but this evolution brings unprecedented challenges in data quality, complexity, and integration.

Abivax dazzled investors and analysts with positive data from a pair of Phase III induction trials assessing obefazimod in adults with moderately to severely active ulcerative colitis. The results ...